Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BC1618
Cat. No.:
0225LY-1026
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
BC1618 is an orally active inhibitor of Fbxo48 that enhances hepatic insulin sensitivity and promotes mitochondrial fission and autophagy via AMPK signaling.
Synonym:
2-Propanol, 1-[bis(phenylmethyl)amino]-3-[4-(trifluoromethyl)phenoxy]-; 2222094-18-8; 1-(Dibenzylamino)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol; 1-(Dibenzylamino)-3-[4-(trifluoromethyl)phenoxy]propan-2-ol=
CAS No.:
2222094-18-8
Compound CID:
134417552
Formula:
C24H24F3NO2
Formula Weight:
415.45
Specification
Relative Density:
1.223 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BC1618 can be used in neurobiology research to investigate the promotion of axonal regeneration through the modulation of specific signaling pathways.
Library Information
Target:
AMPK; E1/E2/E3 Enzyme
Receptor:
AMPK; E1/E2/E3 Enzyme; Fbxo48
Pathways:
Autophagy; Ubiquitination; PI3K/Akt/mTOR signaling; Chromatin/Epigenetic
Plate Number:
AOCL-14
Plate Location:
b9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
100 mg/mL; 240.7 mM
